Sentigen Acquisition Gives Invitrogen First Major GPCR Screening Play, Boosts Cell Provision Biz | GenomeWeb
Invitrogen said last week that it will acquire cell-based assay company Sentigen Holding for around $25.9 million in cash, significantly bolstering a relatively thin portfolio for GPCR screening and building on its kinase and ion channel drug screening products.
Invitrogen hopes it can boost sales of Sentigen’s relatively young and unproven Tango GPCR screening technology through its significant marketing muscle and by combining Tango with its popular GeneBLAzer reporter gene assay products.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.